Romero-Reyes
M, Salvemini D.
Cancer and
Orofacial Pain.
Med
Oral Patol Oral Cir Bucal. 2016 Nov 1;21
(6):e665-71.
doi:10.4317/medoral.21515
http://dx.doi.org/doi:10.4317/medoral.21515
|
1.
Benoliel R, Epstein J, Eliav E, Jurevic R, Elad S. Orofacial pain in cancer:
part I-mechanisms. J Dent Res. 2007;86:491-505. |
||||
|
|
||||
|
2.
Clark GT, Ram S. Orofacial pain and neurosensory disorders and dysfunction in
cancer patients. Dent Clin North Am. 2008;52:183-202. |
||||
|
|
||||
|
3.
Romero-Reyes M, Teruel A, Ye Y. Cancer and Referred Facial Pain. Curr Pain
Headache Rep. 2015;19:1-9. |
||||
|
|
||||
|
4.
Schmidt BL. The Neurobiology of Cancer Pain. J Oral Maxillofac Surg.
2015;73(12 Suppl):S132-5. |
||||
|
|
||||
|
5.
Johnston M, Yu E, Kim J. Perineural invasion and spread in head and neck
cancer. Expert Review of Anticancer Therapy. 2012;12:359-71. |
||||
|
|
||||
|
6.
Bapat AA, Hostetter G, Von Hoff DD, Han H. Perineural invasion and associated
pain in pancreatic cancer. Nat Rev Cancer. 2011;11:695-707. |
||||
|
|
||||
|
7.
Binmadi NO, Basile JR. Perineural invasion in oral squamous cell carcinoma: A
discussion of significance and review of the literature. Oral oncology.
2011;47:1005-10. |
||||
|
|
||||
|
8.
Frunza A, Slavescu D, Lascar I. Perineural invasion in head and neck cancers
- a review. Journal of medicine and life. 2014;7:121-3. |
||||
|
|
||||
|
9.
Nemec SF, Herneth AM, Czerny C. Perineural tumor spread in malignant head and
neck tumors. Topics in magnetic resonance imaging:TMRI. 2007;18:467-71. |
||||
|
|
||||
|
10.
Mantyh PW. Cancer pain and its impact on diagnosis, survival and quality of
life. Nature reviews Neuroscience. 2006;7:797-809. |
||||
|
|
||||
|
11.
Schmidt BL, Hamamoto DT, Simone DA, Wilcox GL. Mechanism of cancer pain.
Molecular interventions. 2010;10:164-78. |
||||
|
|
||||
|
12.
Schmidt BL. What pain tells us about cancer. Pain. 2015;156:S32-S4. |
||||
|
|
||||
|
13.
Ye Y, Ono K, Bernab DG, Viet CT, Pickering V, Dolan JC, et al. Adenosine
triphosphate drives head and neck cancer pain through P2X2/3 heterotrimers.
Acta Neuropathologica Communications. 2014;2:62. |
||||
|
|
||||
|
14.
Ye Y, Dang D, Zhang J, Viet CT, Lam DK, Dolan J, et al. Nerve growth factor
links oral cancer progression, pain, and cachexia. Molecular Cancer
Therapeutics. 2011;10:1667-76. |
||||
|
|
||||
|
15.
Bagan J, Sarrion G, Jimenez Y. Oral cancer: Clinical features. Oral oncology.
2010;46:414-7. |
||||
|
|
||||
|
16.
Gorsky M, Epstein JB, Oakley C, Le ND, Hay J, Stevenson-Moore P. Carcinoma of
the tongue: a case series analysis of clinical presentation, risk factors,
staging, and outcome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod.
2004;98:546-52. |
||||
|
|
||||
|
17.
Cuffari L, Siqueira JTT, Nemr K, Rapaport A. Pain complaint as the first
symptom of oral cancer: A descriptive study. Oral Surgery Oral Medicine Oral
Pathology Oral Radiology and Endodontology. 2006;102:56-61. |
||||
|
|
||||
|
18.
Viet CT, Ye Y, Dang D, Lam DK, Achdjian S, Zhang J, et al. Re-expression of
the methylatedEDNRBgene in oral squamous cell carcinoma attenuates
cancer-induced pain. Pain. 2011;152:2323-32. |
||||
|
|
||||
|
19.
Pickering V, Gupta RJ, Quang P, Jordan RC, Schmidt BL. Effect of peripheral
endothelin-1 concentration on carcinoma-induced pain in mice. European
Journal of Pain. 2008;12:293-300. |
||||
|
|
||||
|
20.
Schmidt BL, Pickering V, Liu S, Quang P, Dolan J, Connelly ST, et al.
Peripheral endothelin A receptor antagonism attenuates carcinoma-induced
pain. European Journal of Pain. 2007;11:406-14. |
||||
|
|
||||
|
21.
Lam DK, Dang D, Zhang J, Dolan JC, Schmidt BL. Novel animal models of acute
and chronic cancer pain: a pivotal role for PAR2. The Journal of
neuroscience: the official journal of the Society for Neuroscience.
2012;32:14178-83. |
||||
|
|
||||
|
22.
Lam DK, Schmidt BL. Orofacial pain onset predicts transition to head and neck
cancer. Pain. 2011;152:1206-9. |
||||
|
|
||||
|
23.
Talmi YP, Waller A, Bercovici M, Horowitz Z, Pfeffer MR, Adunski A, et al.
Pain experienced by patients with terminal head and neck carcinoma. Cancer.
1997;80:1117-23. |
||||
|
|
||||
|
24.
Boerman RH, Maassen EM, Joosten J, Kaanders HA, Marres HA, van Overbeeke J,
et al. Trigeminal neuropathy secondary to perineural invasion of head and
neck carcinomas. Neurology. 1999;53:213-6. |
||||
|
|
||||
|
25.
Reiter S, Gavish A, Winocur E, Emodi-Perlman A, Eli I. Nasopharyngeal
carcinoma mimicking a temporomandibular disorder: a case report. Journal of
orofacial pain. 2006;20:74-81. |
||||
|
|
||||
|
26.
Mackie AM, Epstein JB, Wu JS, Stevenson-Moore P. Nasopharyngeal carcinoma:
the role of the dentist in assessment, early diagnosis and care before and
after cancer therapy. Oral Oncol. 2000;36:397-403. |
||||
|
|
||||
|
27.
Gronseth G, Cruccu G, Alksne J, Argoff C, Brainin M, Burchiel K, et al.
Practice Parameter: The diagnostic evaluation and treatment of trigeminal
neuralgia (an evidence-based review): Report of the Quality Standards
Subcommittee of the American Academy of Neurology and the European Federation
of Neurological Societies. Neurology. 2008;71:1183-90. |
||||
|
|
||||
|
28.
Moazzam AA, Habibian M. Patients appearing to dental professionals with
orofacial pain arising from intracranial tumors: a literature review. Oral
Surgery Oral Medicine Oral Pathology and Oral Radiology. 2012;114:749-55. |
||||
|
|
||||
|
29.
D'Silva NJ, Summerlin DJ, Cordell KG, Abdelsayed RA, Tomich CE, Hanks CT, et
al. Metastatic tumors in the jaws: a retrospective study of 114 cases. J Am
Dent Assoc. 2006;137:1667-72. |
||||
|
|
||||
|
30.
Hirshberg A, Shnaiderman-Shapiro A, Kaplan I, Berger R. Metastatic tumours to
the oral cavity - Pathogenesis and analysis of 673 cases. Oral oncology.
2008;44:743-52. |
||||
|
|
||||
|
31.
Murillo J, Bagan JV, Hens E, Diaz JM, Leopoldo M. Tumors Metastasizing to the
Oral Cavity: A Study of 16 Cases. Journal of Oral and Maxillofacial Surgery.
2013;71:1545-51. |
||||
|
|
||||
|
32.
Lawes KP, Danford M, Di Palma S. Delayed metastasis to the mandible of
esophageal adenocarcinoma. Head Neck Pathol. 2013;7:416-20. |
||||
|
|
||||
|
33.
Seoane J, Van der Waal I, Van der Waal RIF, Cameselle-Teijeiro J, Antn I,
Tardio A, et al. Metastatic tumours to the oral cavity: a survival study with
a special focus on gingival metastases. Journal of clinical periodontology.
2009;36:488-92. |
||||
|
|
||||
|
34.
Iriarte Soldevilla JI, Unda Urziz M, Angulo Cuesta J, Zubiaur Lbano C,
Arceo R, Flores Corral N. [Trigeminal neuralgia. First manifestation of
adenocarcinoma of the prostate]. Arch Esp Urol. 1993;46:54-6. |
||||
|
|
||||
|
35.
Albayram S, Adaletli I, Selcuk H, Gulsen F, Islak C, Kocer N. Breast Cancer
Metastasis Involving Pterygopalatine Fossa: A Cause of Trigeminal Neuralgia.
Headache: The Journal of Head and Face Pain. 2004;44:927-8. |
||||
|
|
||||
|
36.
Kruse ALD, Luebbers HT, Obwegeser JA, Edelmann L, Graetz KW.
Temporomandibular disorders associated with metastases to the
temporomandibular joint: a review of the literature and 3 additional cases.
Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology.
2010;110:e21-e8. |
||||
|
|
||||
|
37.
Schoenen J, Broux R, Moonen G. Unilateral Facial Pain as the First Symptom of
Lung Cancer: Are there Diagnostic Clues? Cephalalgia. 1992;12:178-9. |
||||
|
|
||||
|
38.
Pembroke CA, Byrne A, Lester JF, Button M. Persistent unilateral facial pain
in lung cancer patients with mediastinal nodal involvement. Lung Cancer.
2013;82:173-5. |
||||
|
|
||||
|
39.
Bindoff LA, Heseltine D. Unilateral facial pain in patients with lung cancer:
a referred pain via the vagus? Lancet. 1988;1(8589):812-5. |
||||
|
|
||||
|
40.
Sarlani E, Schwartz AH, Greenspan JD, Grace EG. Facial Pain as First
Manifestation of Lung Cancer: A Case of Lung Cancer-Related Cluster Headache
and a Review of the Literature. Journal of orofacial pain. 2003;17:262-7. |
||||
|
|
||||
|
41.
Capobianco DJ. Facial Pain as a Symptom of Nonmetastatic Lung Cancer.
Headache: The Journal of Head and Face Pain. 1995;35:581-5. |
||||
|
|
||||
|
42.
Dach F, Oliveira FAA, dos Santos AC, Speciali JG. Trigeminal Neuralgia as the
Sole Symptom of Pancreatic Cancer. Headache: The Journal of Head and Face
Pain. 2013;53:165-7. |
||||
|
|
||||
|
43.
Webber B, Webber M, Keinan D. Extranodal large B cell lymphoma of the
anterior maxilla. Case report and review of literature. The New York state
dental journal. 2015;81:34-8. |
||||
|
|
||||
|
44.
Parihar S, Garg RK, Narain P. Primary extra-nodal non-Hodgkin's lymphoma of
gingiva: A diagnostic dilemma. Journal of oral and maxillofacial pathology:
Jomfp. 2013;17:320. |
||||
|
|
||||
|
45.
Oranger A, Carbone C, Izzo M, Grano M. Cellular mechanisms of multiple
myeloma bone disease. Clinical & developmental immunology.
2013;2013:289458. |
||||
|
|
||||
|
46.
Troeltzsch M, Oduncu F, Mayr D, Ehrenfeld M, Pautke C, Otto S. Root
resorption caused by jaw infiltration of multiple myeloma: report of a case
and literature review. J Endod. 2014;40:1260-4. |
||||
|
|
||||
|
47.
Assaf AT, Jrgens TP, Benecke AW, Riecke B, Blessmann M, Zrnc TA, et al. Numb
Chin Syndrome: A Rare and Often Overlooked Symptom. Journal of Oral &
Facial Pain & Headache. 2014;28:80-90. |
||||
|
|
||||
|
48.
Romo CG, Jain P, Cortes JE. Numb chin syndrome by precursor B acute
lymphoblastic leukemia. American journal of hematology. 2014;89:860-1. |
||||
|
|
||||
|
49.
Reddy CG, Mauermann ML, Solomon BM, Ringler MD, Jerath NU, Begna KH, et al.
Neuroleukemiosis: an unusual cause of peripheral neuropathy. Leukemia &
Lymphoma. 2012;53:2405-11. |
||||
|
|
||||
|
50.
Pelosof LC, Gerber DE. Paraneoplastic Syndromes: An Approach to Diagnosis and
Treatment. Mayo Clinic Proceedings. 2010;85:838-54. |
||||
|
|
||||
|
51.
Epstein JB, Elad S, Eliav E, Jurevic R, Benoliel R. Orofacial pain in cancer:
part II--clinical perspectives and management. J Dent Res. 2007;86:506-18. |
||||
|
|
||||
|
52.
Demarquay G, Didelot A, Rogemond V, Ryvlin P, Gouttard M, Garassus P, et al.
Facial pain as first manifestation of anti-Hu paraneoplastic syndrome. The
journal of headache and pain. 2010;11:355-7. |
||||
|
|
||||
|
53.
Romero-Reyes M, Head C, Cacalano NA, Jewett A. Potent induction of TNF-alpha
during interaction of immune effectors with oral tumors as a potential
mechanism for the loss of NK cell viability and function. Apoptosis.
2007;12:2063-75. |
||||
|
|
||||
|
54.
Jewett A, Cacalano NA, Teruel A, Romero M, Rashedi M, Wang M, et al.
Inhibition of nuclear factor kappa B (NFkappaB) activity in oral tumor cells
prevents depletion of NK cells and increases their functional activation.
Cancer immunology, immunotherapy: CII. 2006;55:1052-63. |
||||
|
|
||||
|
55.
Magee MS, Snook AE, Marszalowicz GP, Waldman SA. Immunotherapeutic strategies
to target prognostic and predictive markers of cancer. Biomarkers in
medicine. 2013;7:23-35. |
||||
|
|
||||
|
56.
van den Beuken-van Everdingen M, de Rijke J, Kessels A, Schouten H, van Kleef
M, Patijn J. Prevalence of pain in patients with cancer: a systematic review
of the past 40 years. Annals of Oncology. 2007;18:1437-49. |
||||
|
|
||||
|
57.
Carozzi VA, Canta A, Chiorazzi A. Chemotherapy-induced peripheral neuropathy:
What do we know about mechanisms? Neurosci Lett. 2015;596:90-107. |
||||
|
|
||||
|
58.
Binczak M, Navez M, Perrichon C, Blanchard D, Bollet M, Calmels P, et al.
Management of somatic pain induced by head-and-neck cancer treatment:
Definition and assessment. Guidelines of the French Oto-Rhino-Laryngology-
Head and Neck Surgery Society (SFORL). European Annals of
Otorhinolaryngology, Head and Neck Diseases. 2014;131:243-7. |
||||
|
|
||||
|
59.
Campos MI, Campos CN, Aarestrup FM, Aarestrup BJ. Oral mucositis in cancer
treatment: Natural history, prevention and treatment. Molecular and clinical
oncology. 2014;2:337-40. |
||||
|
|
||||
|
60.
Barkokebas A, Silva IH, de Andrade SC, Carvalho AA, Gueiros LA, Paiva SM, et
al. Impact of oral mucositis on oral-health-related quality of life of
patients diagnosed with cancer. J Oral Pathol Med. 2015;44:746-51. |
||||
|
|
||||
|
61.
Jawad H, Hodson NA, Nixon PJ. A review of dental treatment of head and neck
cancer patients, before, during and after radiotherapy: part 2. Br Dent J.
2015;218:69-74. |
||||
|
|
||||
|
62.
Viet CT, Corby PM, Akinwande A, Schmidt BL. Review of Preclinical Studies on
Treatment of Mucositis and Associated Pain. Journal of Dental Research.
2014;93:868-75. |
||||
|
|
||||
|
63.
Connolly I, Zaleon C, Montagnini M. Management of Severe Neuropathic Cancer
Pain: An Illustrative Case and Review. American Journal of Hospice and
Palliative Medicine. 2013;30:83-90. |
||||
|
|
||||
|
64.
Scott-Warren J, Bhaskar A. Cancer pain management-Part I: General principles.
Continuing Education in Anaesthesia, Critical Care & Pain. 2014. p.
285-91. |
||||
|
|
||||
|
65.
Steiner F, Evans J, Marsh R, Rigby P, James S, Sutherland K, et al. Mouth
opening and trismus in patients undergoing curative treatment for head and
neck cancer. International journal of oral and maxillofacial surgery.
2015;44:292-6. |
||||
|
|
||||
|
66.
Jawad H, Hodson NA, Nixon PJ. A review of dental treatment of head and neck
cancer patients, before, during and after radiotherapy: part 1. Br Dent J.
2015;218:65-8. |
||||
|
|
||||
|
67.
Clark GT, Ram S. Orofacial Pain and Neurosensory Disorders and Dysfunction in
Cancer Patients. Dental Clinics of North America. 2008;52:183-202. |
||||
|
|
||||
|
68.
Sharp H, Morris JC, Van Waes C, Gius D, Cooley-Zgela T, Singh AK. High
incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and
concurrent external beam radiation for locally advanced head and neck
cancers. American journal of clinical oncology. 2008;31:557-60. |
||||
|
|
||||
|
69.
Cockerham MB, Weinberger BB, Lerchie SB. Oral Glutamine for the Prevention of
Oral Mucositis Associated with High-Dose Paclitaxel and Melphalan for
Autologous Bone Marrow Transplantation. Annals of Pharmacotherapy.
2000;34:300-3. |
||||
|
|
||||
|
70.
Grau JJ, Caballero M, Verger E, Monz M, Blanch Jl. Weekly paclitaxel for
platin-resistant stage IV head and neck cancer patients. Acta
oto-laryngologica. 2009;129:1294-9. |
||||
|
|
||||
|
71.
Doyle T, Chen Z, Muscoli C, Bryant L, Esposito E, Cuzzocrea S, et al.
Targeting the Overproduction of Peroxynitrite for the Prevention and Reversal
of Paclitaxel-Induced Neuropathic Pain. The Journal of Neuroscience.
2012;32:6149-60. |
||||
|
|
||||
|
72.
Little JW, Doyle T, Salvemini D. Reactive nitroxidative species and
nociceptive processing: determining the roles for nitric oxide, superoxide,
and peroxynitrite in pain. Amino acids. 2012;42:75-94. |
||||
|
|
||||
|
73.
Salvemini D, Little JW, Doyle T, Neumann WL. Roles of reactive oxygen and
nitrogen species in pain. Free Radical Biology and Medicine. 2011;51:951-66. |
||||
|
|
||||
|
74.
Janes K, Esposito E, Doyle T, Cuzzocrea S, Tosh DK, Jacobson KA, et al. A(3)
adenosine receptor agonist prevents the development of paclitaxel-induced
neuropathic pain by modulating spinal glial-restricted redox-dependent
signaling pathways. Pain. 2014;155:2560-7. |
||||
|
|
||||
|
75.
Janes K, Symons-Liguori AM, Jacobson KA, Salvemini D. Identification of A3
adenosine receptor agonists as novel non-narcotic analgesics. British Journal
of Pharmacology. 2016;173:1253-67. |
||||
|
|
||||
|
76.
Chen Z, Janes K, Chen C, Doyle T, Bryant L, Tosh DK, et al. Controlling
murine and rat chronic pain through A3 adenosine receptor activation. The
FASEB Journal. 2012;26:1855-65. |
||||
|
|
||||
|
77.
Little JW, Ford A, Symons-Liguori AM, Chen Z, Janes K, Doyle T, et al.
Endogenous adenosine A3 receptor activation selectively alleviates persistent
pain states. Brain. 2015;138:28-35. |
||||
|
|
||||
|
78.
Janes K, Little JW, Li C, Bryant L, Chen C, Chen Z, et al. The Development
and Maintenance of Paclitaxel-induced Neuropathic Pain Require Activation of
the Sphingosine 1-Phosphate Receptor Subtype 1. Journal of Biological
Chemistry. 2014;289:21082-97. |
||||
|
|
||||
|
79.
Janes K, Wahlman C, Little JW, Doyle T, Tosh DK, Jacobson KA, et al. Spinal
neuroimmune activation is independent of T-cell infiltration and attenuated
by A3 adenosine receptor agonists in a model of oxaliplatin-induced
peripheral neuropathy. Brain, behavior, and immunity. 2015;44:91-9. |
||||
|
|
||||
|
80.
Varani K, Vincenzi F, Targa M, Paradiso B, Parrilli A, Fini M, et al. The
stimulation of A3 adenosine receptors reduces bone-residing breast cancer in
a rat preclinical model. European Journal of Cancer. 2013;49:482-91. |
||||
|
|
||||
|
81.
Tosh DK, Padia J, Salvemini D, Jacobson KA. Efficient, large-scale synthesis
and preclinical studies of MRS5698, a highly selective A3 adenosine receptor
agonist that protects against chronic neuropathic pain. Purinergic Signal.
2015;11:371-87. |
||||
|
|
||||
|
82.
Fishman P, Bar-Yehuda S, Liang BT, Jacobson KA. Pharmacological and
therapeutic effects of A3 adenosine receptor agonists. Drug Discov Today.
2012;17:359-66. |
||||